Biopharmaceuticals

4D Pharma has announced positive topline results from Part A of its Phase I/II clinical trial of MRx-4DP0004, an orally-delivered single strain Live Biotherapeutic being developed for the treatment of asthma.  Part A  The Phase I/II trial is a multi-center, double-blind, placebo-controlled study in patients with partly controlled asthma taking long-term medication. The primary endpoint […]

Noorik Biopharmaceuticals, a clinical-stage biopharmaceutical company repurposing micro-dose ambrisentan for the treatment of kidney, liver, and respiratory diseases, signed a contract with the Federal Government of Switzerland to develop ambrisentan as a treatment for patients with severe Covid-19.   Why?  The investment, under the Federal Funding Programme for Covid-19 Medicines initiative, will enable the acceleration of the clinical development of ambrisentan. The contract will […]

Australian biopharmaceutical company Cholrem have produced CAVADEX (Beta-Cyclodextrin), a product which removes cholesterol from damaged and narrowed arteries after a few months of treatment, leading to increased blood flow.  Context Atherosclerosis, also known as heart disease, is reportedly the western world’s number one killer of people. This disease results from the accumulation of cholesterol in the arteries. […]

The latest sponsored DDW Sitting Down With podcast features Lisa Moneymaker and Paul O’Donohoe of Medidata and they talk to us about decentralised clinical trials. Medidata technology has helped to bring Covid-19 vaccines and treatments to market in record timelines and the company was the first to have launched a fully end-to-end Decentralised Clinical Trials (DCT) offering.  Decentralised clinical trials, described as the ‘new normal’ and the future of […]

The latest sponsored DDW Sitting Down With podcast features Lisa Moneymaker and Paul O’Donohoe of Medidata and they talk to us about decentralised clinical trials. Medidata technology has helped to bring Covid-19 vaccines and treatments to market in record timelines and the company was the first to have launched a fully end-to-end Decentralised Clinical Trials (DCT) offering.  Decentralised clinical trials, described as the ‘new normal’ and the future of […]

Nykode Therapeutics (formerly Vaccibody) has entered into a license and collaboration agreement with Regeneron for the discovery, development and commercialisation of potential new vaccines for cancer and infectious diseases.  What is the structure of the agreement?  The agreement includes five programmes, three within cancer and two within infectious diseases. Each of these may include several vaccine candidates, all of […]

Listen to this article on the DDW Podcast:   The workload in pharmacovigilance (PV) is soaring and as new vaccines and medications enter the market, it’s crucial to track adverse events (AE). As AE reports still have to be filed within 24 hours, Kathleen O’Brien of Amplexor Life Sciences lays out a blueprint for centralising global AE reporting.  AE notifications come in […]

Target class-specific libraries mean you need to screen less to identify high-quality antibodies. Aaron Sato, Chief Scientific Officer at Twist Bioscience, elaborates. Antibody developers are increasingly utilising antibody libraries to derive high-quality, drug-like biologics. However, only a few general-purpose libraries have been commercially available for drug discovery. As a result, most approved library-derived antibodies originate […]

News round-up by DDW’s Megan Thomas for 1-5 November DDW’s Megan Thomas has selected five stories which showcase the international scope of the drug discovery industry in terms of research, innovation, collaboration and development. 1. New consortium to boost Covid-19 vaccine production in South Africa The Medicines Patent Pool (MPP), the World Health Organization (WHO), […]

Abcam has completed a $340m strategic acquisition of BioVision and doubled the footprint of its immunoassay kit R&D and manufacturing facility in Eugene, Oregon. This enhanced capacity is another component of Abcam’s growth in the US, which the company says will enable it to support the research and biopharma sector globally.  The addition of BioVision enhances Abcam’s […]

Ahead of COP26, which began on October 31 in Glasgow and runs until November 12, the Association of the British Pharmaceutical Industry (ABPI) led a joint statement from the pharmaceutical industry alongside other global associations.   Organisations included in the statement were: The European Federation of Pharmaceutical Industries and Associations (EFPIA), Farmindustria, IMC, The International Federation of […]

Valo Health is a technology company built to transform drug discovery and development using human-centric data and artificial intelligence-powered compute. VP of Integrated Research, Guido Lanza talks to DDW in its Drug Discovery 2021 supplement about how Valo Health is re-inventing and innovating to overcome the fragmented, outdated drug discovery and development process that exists today.  According […]

PharmaLex Group has announced the launch of a new service line, Biopharma Excellence, and the appointment of ex-MHRA scientific lead Dr Christian Schneider as its Chief Medical Officer.   Biopharma Excellence is a fusion of three scientific organisations, PharmaLex, ERA Consulting and Biopharma Excellence, under the PharmaLex brand. The new service line combines 35+ years of empirical experience and respected regulator […]

AstraZeneca will present data across its Covid-19 and respiratory syncytial virus (RSV) pipeline as three late-breaking oral presentations at the 10th Annual IDWeek Virtual Conference, September 29 to October 3, 2021, illustrating its commitment to advancing innovative science in infectious diseases.  The presentations include AZD7442 long-acting antibody combination Phase III PROVENT trial prevention data and Vaxzevria Phase III analysis investigating […]

By Amanda Turner, Senior Product Manager for Custom Antibody Products at Bio-Rad and Laura Moriarty, Senior Marketing Manager at Bio-Rad The global market for therapeutic antibodies represents a huge and ever-expanding opportunity for pharmaceutical developers, with the market for monoclonal antibody therapies alone being estimated to reach $300 billion by 2025.1 However, the value of […]

India has a rapidly growing pharmaceutical market that, being the third largest pharmaceutical industry in the world by volume, holds a prominent place in global health. Over the last decade, the Indian pharmaceutical market has seen increasing domestic and foreign investment. While the overall number of deals fluctuated only slightly between 2011 and 2019, a […]